Bladder cancer
Molecular diagnostics in the era of targeted therapies for mUCaFarid (65 years old)
Farid, 65 years old, devotes his time to mentoring young entrepreneurs at a startup incubator, sharing his wisdom and experience to help them succeed. He initially presented with UCa of the bladder with bone and lymph node metastases and was treated with 6 cycles of gemcitabine + cisplatin. After progression with new bone metastases, he received pembrolizumab, but the treatment was stopped after 10 cycles due to grade 4 immune-related colitis.
Assessment summary:
- ECOG PS: 1
- Peripheral neuropathy: grade 1 due to prior cisplatin
- No hearing impairment
- GFR: 70 ml/min
- Medical history: mild hypertension, hyperthyroidism
- Lymph node biopsy testing results: FGFR3 wild type
After complete recovery from the immune-related colitis, the patient shows disease progression.